Back

The clinically active PARP inhibitor olaparib ameliorates doxorubicin-induced cardiotoxicity in both in vitro and in vivo model

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Molecular cardio-oncology Drugs, Drug Targets ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Ms Dongqing Chen

University of Newcastle, Newcastle (Australia)

5 More presentations in this session

Presentation thumbnail
Heart failure stimulates colorectal tumour growth through gut microbial alterations of specific populations
Ms S. De Wit (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Cardiometabolic rewiring in the context of doxorubicin-induced cardiotoxicity: fuel preference changes from fatty acids to glucose oxidation
Doctor G. Guerra (Turin, IT)
Abstract Slides Video
Presentation thumbnail
Rapamycin ameliorates doxorubicin-induced cardiomyopathy through suppression of RIPK1-independent necroptosis
Doctor M. Shimizu (Sapporo, JP)
Abstract Slides Video
Presentation thumbnail
CaMKIIdelta-mediated SR Ca leak contributes to long-term Doxorubicin-induced cardiotoxicity
Miss A. Feder (DE)
Abstract Slides Video
Presentation thumbnail
Glycogen Synthase Kinase 3 beta confers refractoriness to the microRNA-210-elicited exacerbation of hypoxia-reoxygenation stress-induced apoptotic cell death
Doctor G. Marwarha (Trondheim, NO)
Abstract Slides

Access the full session

Session thumbnail
Molecular cardio-oncology

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources